Monopar Therapeutics Inc. (MNPR) Research

Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mucobuccal tablet, is currently undergoing Phase 2b/3 clinical trials. This therapy aims to prevent severe oral mucositis, a debilitating side effect of chemoradiotherapy, in patients suffering from oropharyngeal cancer. The company's pipeline also includes Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for advanced soft tissue sarcoma. Furthermore, Monopar is developing MNPR-101, an antibody engineered to target the urokinase plasminogen activator receptor (uPAR) for various cancer indications. A radioimmunotherapeutic variant of MNPR-101, named MNPR-101 RIT, is being explored for its potential in both cancer therapy and the treatment of severe COVID-19. Another promising compound, MNPR-202, an analog of camsirubicin, is being developed to potentially address cancers that have developed resistance to doxorubicin and camsirubicin. Monopar Therapeutics Inc. maintains strategic partnerships, including one with the Grupo Español de Investigación en Sarcomas (GEIS) for the advancement of camsirubicin in patients with advanced soft tissue sarcoma. They also collaborate with NorthStar Medical Radioisotopes, LLC on the development of radio-immunotherapeutics targeting severe COVID-19, and with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related compounds across different cancer types. The company was established in 2014 and its corporate headquarters are situated in Wilmette, Illinois.

Open Monopar Therapeutics Inc. (MNPR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.